Reference
Babic JS, et al. Real-life data on the efficacy and safety of ombitasvir/paritaprevir//ritonavir + dasabuvir + ribavirin in the patients with genotype 1 chronic hepatitis c virus infection in serbia. Vojnosanitetski Pregled. Military-Medical and Pharmaceutical Review 76: 531-536, No. 5, 2019. Available from: URL: http://doi.org/10.2298/VSP170727186S - Serbia
Rights and permissions
About this article
Cite this article
Antivirals. Reactions Weekly 1768, 50 (2019). https://doi.org/10.1007/s40278-019-66735-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-66735-7